Key Takeaways
Two patients developed choroidal lymphoid hyperplasia associated with vision loss after starting treatment with the GLP-1 receptor agonist dulaglutide.
Visual acuity and systemic lymphadenopathy improved or normalized soon after discontinuing the drug.
While the timing suggests an association between the condition and the drug, the biological explanation remains unclear.
Two patients taking the GLP-1 receptor agonist dulaglutide (Trulicity) developed choroidal lymphoid hyperplasia (CLH), a rare, benign condition of the uveal tract, that resolved after the patients stopped the drug.
